Deutsch
 
Hilfe Datenschutzhinweis Impressum
  DetailsucheBrowse

Datensatz

 
 
DownloadE-Mail
  Models of Models: A Translational Route for Cancer Treatment and Drug Development

Ogilvie, L. A., Kovachev, A., Wierling, C., Lange, B. M. H., & Lehrach, H. (2017). Models of Models: A Translational Route for Cancer Treatment and Drug Development. Frontiers in Oncology, 7: 7:219. doi:10.3389/fonc.2017.00219.

Item is

Basisdaten

einblenden: ausblenden:
Genre: Zeitschriftenartikel

Dateien

einblenden: Dateien
ausblenden: Dateien
:
Ogilvie.pdf (Verlagsversion), 345KB
Name:
Ogilvie.pdf
Beschreibung:
-
OA-Status:
Sichtbarkeit:
Öffentlich
MIME-Typ / Prüfsumme:
application/pdf / [MD5]
Technische Metadaten:
Copyright Datum:
-
Copyright Info:
© 2017 Ogilvie, Kovachev, Wierling, Lange and Lehrach

Externe Referenzen

einblenden:
ausblenden:
externe Referenz:
https://www.ncbi.nlm.nih.gov/pubmed/28971064 (beliebiger Volltext)
Beschreibung:
-
OA-Status:

Urheber

einblenden:
ausblenden:
 Urheber:
Ogilvie, L. A.1, Autor
Kovachev, A.1, Autor
Wierling, C.1, Autor
Lange, B. M. H.1, Autor
Lehrach, H.1, 2, Autor           
Affiliations:
1Alacris Theranostics GmbH, Berlin, Germany, ou_persistent22              
2Emeritus Group of Vertebrate Genomics (Head: Hans Lehrach), Max Planck Institute for Molecular Genetics, Max Planck Society, ou_2385697              

Inhalt

einblenden:
ausblenden:
Schlagwörter: computational model genetically engineered mouse models mechanistic modeling model optimization preclinical models transgenic mice
 Zusammenfassung: Every patient and every disease is different. Each patient therefore requires a personalized treatment approach. For technical reasons, a personalized approach is feasible for treatment strategies such as surgery, but not for drug-based therapy or drug development. The development of individual mechanistic models of the disease process in every patient offers the possibility of attaining truly personalized drug-based therapy and prevention. The concept of virtual clinical trials and the integrated use of in silico, in vitro, and in vivo models in preclinical development could lead to significant gains in efficiency and order of magnitude increases in the cost effectiveness of drug development and approval. We have developed mechanistic computational models of large-scale cellular signal transduction networks for prediction of drug effects and functional responses, based on patient-specific multi-level omics profiles. However, a major barrier to the use of such models in a clinical and developmental context is the reliability of predictions. Here we detail how the approach of using "models of models" has the potential to impact cancer treatment and drug development. We describe the iterative refinement process that leverages the flexibility of experimental systems to generate highly dimensional data, which can be used to train and validate computational model parameters and improve model predictions. In this way, highly optimized computational models with robust predictive capacity can be generated. Such models open up a number of opportunities for cancer drug treatment and development, from enhancing the design of experimental studies, reducing costs, and improving animal welfare, to increasing the translational value of results generated.

Details

einblenden:
ausblenden:
Sprache(n): eng - English
 Datum: 2017-09-012017-09-192017
 Publikationsstatus: Erschienen
 Seiten: -
 Ort, Verlag, Ausgabe: -
 Inhaltsverzeichnis: -
 Art der Begutachtung: -
 Identifikatoren: DOI: 10.3389/fonc.2017.00219
ISSN: 2234-943X (Print)
 Art des Abschluß: -

Veranstaltung

einblenden:

Entscheidung

einblenden:

Projektinformation

einblenden:

Quelle 1

einblenden:
ausblenden:
Titel: Frontiers in Oncology
Genre der Quelle: Zeitschrift
 Urheber:
Affiliations:
Ort, Verlag, Ausgabe: Lausanne : Frontiers Media
Seiten: - Band / Heft: 7 Artikelnummer: 7:219 Start- / Endseite: - Identifikator: ISSN: 2234-943X
CoNE: https://pure.mpg.de/cone/journals/resource/2234-943X